oral solution

Breakthrough Formula Advantages:

✔ Dual Mechanism

• Enrofloxacin (100mg/ml): 3rd-gen fluoroquinolone targeting resistant respiratory pathogens

• N-Acetyl L-Cysteine (186mg/ml): Potent mucolytic to dissolve viscous secretions and improve breathing

✔ Enhanced Bioavailability

• Propylene glycol matrix ensures rapid absorption and tissue penetration

✔ Clinical Superiority

• 27% faster recovery vs. standard enrofloxacin in field trials

• Effective against Mycoplasma-CRD complexes where single antibiotics fail

Targeted Indications:

Primary Battles:
✓ Chronic Respiratory Disease (CRD)
✓ Mycoplasmosis (MS & MG strains)
✓ Infectious Coryza (Avibacterium paragallinarum)
✓ Secondary bacterial pneumonias post-IB/AI outbreaks

Pathogen Coverage:

• Gram-negative: E. coli, Pasteurella

• Mycoplasma: gallisepticum, synoviae

• Resistant Strains: Beta-lactamase producers

Precision Dosing Protocol:

• Standard: 10mg/kg BW (1ml per 1-2L water) for 3-5 days

• Severe Cases: Extended 5-day course with 12-hour water dosing